

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### SYNTHESIS AND *IN VITRO* ANTIVIRAL ACTIVITY EVALUATION OF 9-(2-AZIDO-2,3-DIDEOXY- $\beta$ -D-THREO-PENTOFURANOSYL)ADENINE DERIVATIVES

Satoshi Takamatsu<sup>a</sup>; Kunisuke Izawa<sup>a</sup>; Tokumi Maruyama<sup>b</sup>; Satoshi Katayama<sup>a</sup>; Naoko Hirose<sup>a</sup>; Erik De Clercq<sup>c</sup>

<sup>a</sup> AminoScience Laboratories, Ajinomoto Co., Inc., Kawasaki, Kanagawa, Japan <sup>b</sup> Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan <sup>c</sup> Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

Online publication date: 31 March 2001

**To cite this Article** Takamatsu, Satoshi, Izawa, Kunisuke, Maruyama, Tokumi, Katayama, Satoshi, Hirose, Naoko and De Clercq, Erik(2001) 'SYNTHESIS AND *IN VITRO* ANTIVIRAL ACTIVITY EVALUATION OF 9-(2-AZIDO-2,3-DIDEOXY- $\beta$ -D-THREO-PENTOFURANOSYL)ADENINE DERIVATIVES', Nucleosides, Nucleotides and Nucleic Acids, 20: 4, 1053 – 1057

**To link to this Article:** DOI: 10.1081/NCN-100002490

**URL:** <http://dx.doi.org/10.1081/NCN-100002490>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHESIS AND *IN VITRO* ANTIVIRAL ACTIVITY  
EVALUATION OF 9-(2-AZIDO-2,3-DIDEOXY- $\beta$ -D-  
*THREO*-PENTOFURANOSYL)ADENINE  
DERIVATIVES**

**Satoshi Takamatsu, Kunisuke Izawa,<sup>1,\*</sup> Tokumi Maruyama,<sup>2</sup>  
Satoshi Katayama,<sup>1</sup> Naoko Hirose,<sup>1</sup> and Erik De Clercq<sup>3</sup>**

<sup>1</sup>AminoScience Laboratories, Ajinomoto Co., Inc. 1-1, Suzuki-cho,  
Kawasaki-ku, Kawasaki, Kanagawa 210-8681, Japan

<sup>2</sup>Faculty of Pharmaceutical Sciences, Tokushima Bunri University,  
Yamashiro-cho, Tokushima 770-8514, Japan

<sup>3</sup>Rega Institute for Medical Research, Katholieke Universiteit Leuven,  
Minderbroedersstraat 10, Leuven B-3000, Belgium


**ABSTRACT**

9-(2-Azido-2,3-dideoxy- $\beta$ -D-*threo*-pentofuranosyl)adenine derivatives (**1a–e**) containing a lipophilic function at the N-6 position in the purine ring were prepared and evaluated for their antiviral activity. The compounds **1a–e** turned out to be inactive as antiviral agents.

Dideoxynucleoside analogues in which 2'- or 3'-hydrogen in the carbohydrate part is replaced by another atom or functional group have been extensively investigated (1) in drug research and biochemistry. This is because such replacement often enhances biological activity and chemical or metabolic stability of the nucleoside. As an anti-HIV agent, 9-(2,3-dideoxy-2-fluoro- $\beta$ -D-*threo*-pentofuranosyl)adenine (FddA, **2**, (1,2)) is one of the most representative examples of which C2'- $\beta$ -hydrogen in the sugar moiety is substituted with fluorine. Its azido analogue, 9-(2-azido-2,3-dideoxy- $\beta$ -D-*threo*-pentofuranosyl)adenine (AzddA, **3**) has also been reported with quite good anti-HIV activity (1).

---

\*Corresponding author.



In the course of our synthetic investigations (3) on **2**, we developed a key intermediate (**6**) to synthesize C2'-β substituted purine nucleosides. The intermediate is applicable not only for the synthesis of C2'-β fluorinated dideoxynucleosides such as **2**, but also for the synthesis of C2'-β azidated dideoxynucleosides such as **3**. Since the intermediate has the chlorine at the 6 position of purine, it permits the introduction of a variety of substituents at the 6 position. Although a series of 6-substituted amino analogue of FddA has received attention (4), we became interested in the synthesis of AzddA derivatives (**1a-e**) containing a lipophilic function at the N-6 position of the purine ring.

Thus, 6-chloro-9-(3-deoxy-β-D-erythro-pentofuranosyl)-9H-purine (**5**) (**5**) was obtained from inosine (**4**) by the modified Reese method (6) (Fig. 1). The detail of this synthesis will be reported in due course (3). The 5'-hydroxyl group in **5** was selectively protected with 3.3 equivalents of trityl chloride (TrCl) in the presence of triethylamine (Et<sub>3</sub>N) and 4-dimethylaminopyridine (DMAP) in DMF at 50°C. After usual work-up and purification by silica gel chromatography, pure **6** was obtained in 89% yield.

The pivotal intermediate **7** was prepared through the azidation of the C2'-β position of **6** as shown in Figure 1. The 2'-hydroxyl group of **6** was first reacted with trifluoromethanesulfonic anhydride, then treated with sodium azide (NaN<sub>3</sub>) in *N,N*-dimethylformamide at room temperature to afford the desired **7**. After the




Figure 1.



**Table 1.** Anti-HIV-1 and Anti-HIV-2 Activities of **1a–e**

Compound	Strain	EC50 ( $\mu\text{g/ml}$ )	CC50 ( $\mu\text{g/ml}$ )	SI
<b>1a</b>	III <sub>B</sub>	>101	=100.8	<1
	ROD	107	=106.9	<1
<b>1b</b>	III <sub>B</sub>	>115	=115.1	<1
	ROD	>81	=80.7	<1
<b>1c</b>	III <sub>B</sub>	>125	>125	$\times 1$
	ROD	>125	>125	$\times 1$
<b>1d</b>	III <sub>B</sub>	>125	>125	$\times 1$
	ROD	>125	>125	$\times 1$
<b>1e</b>	III <sub>B</sub>	>125	>125	$\times 1$
	ROD	>125	>125	$\times 1$

silica gel column separation, the yield of **7** was 74% in 2 steps. The structure of **7** (7) was confirmed by IR spectrum (the  $2114\text{ cm}^{-1}$  absorption showed the presence of the azido group) and NMR spectrum (the vicinal coupling of H1'-H2' showed the azido substitution at the C2'- $\beta$  position). After the replacement of chlorine at the 6 position of the purine ring in **7** with a variety of mono-alkyl and di-alkyl amines, the trityl group at the 5'-hydroxyl group was hydrolyzed to furnish the desired **1a–e** (8). After the preparative silica gel plate separation, the yields of **1a–e** were 62–100% in 2 steps.

Anti-HIV activity and cytotoxicity for the compounds **1a–e** were evaluated (Table 1). The results indicated that all the compounds were inactive against the replication of HIV-1 (III<sub>B</sub>) and HIV-2 (ROD) at subtoxic concentrations in acutely infected MT-4 cells. These results may mean that compounds **1a–e** are not recognized by adenosine kinase.

In conclusion, 2'- $\beta$ -azido-2',3'-dideoxyadenosine derivatives **1a–e** containing a lipophilic function at the N-6 position in the adenine ring were prepared through the pivotal intermediate **7**. The compounds **1a–e** were evaluated against the cytopathicity of human immunodeficiency virus (HIV) in MT-4 cells. However, **1a–e** turned out to be inactive as anti-HIV agents.

## REFERENCES

- (a) Herdewijn, P.; Pauwels, R.; Baba, M.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* **1987**, *30*, 2131–2137. (b) Pauwels, R.; Baba, M.; Balzarini, J.; Herdewijn, P.; Desmyter, J.; Robins, M. J.; Zou, R.; Madej, D.; De Clercq, E. *Biochem. Pharmacol.* **1988**, *37*, 1317–1325. (c) Herdewijn, P.; Balzarini, J.; Pauwels, R.; Janssen, G.; Van Aerschot, A.; De Clercq, E. *Nucleosides & Nucleotides* **1989**, *8*, 1231–1257.
- Marquez, V. E.; Tseng, C. K.-H.; Kelley, J. A.; Mitsuya, H.; Broder, S.; Roth, J. S.; Driscoll, J. S. *Biochem. Pharmacol.* **1987**, *36*, 2719–2722.



3. To be submitted.
4. (a) Barchi, Jr., J. J.; Marquez, V. E.; Driscoll, J. S.; Ford, Jr., H.; Mitsuya, H.; Shirasaka, T.; Aoki, S.; Kelley, J. A. *J. Med. Chem.* **1991**, *34*, 1647–1655. (b) Driscoll, J. S.; Siddiqui, M. A.; Ford, Jr., H.; Kelley, J. A.; Roth, J. S.; Mitsuya, H.; Tanaka, M.; Marquez, V. E. *J. Med. Chem.* **1996**, *39*, 1619–1625.
5. Kumamoto, H.; Hayakawa, H.; Tanaka, H.; Shindoh, S.; Kato, K.; Miyasaka, T.; Endo, K.; Machida, H.; Matsuda, A. *Nucleosides & Nucleotides* **1998**, *17*, 15–27.
6. Norman, D. G.; Reese, C. B. *Synthesis* **1983**, 304–306.
7. Compound **7**:  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.75 (1H, s, H-2), 8.70 (1H, s, H-8), 7.21–7.43 (15H, m, 5'-O-Tr), 6.58 (1H, d,  $J$  = 6.3 Hz, H-1'), 4.95 (1H, ddd,  $J$  = 9.4, 6.9, 6.3 Hz, H-2'), 4.36–4.46 (1H, m, H-4'), 3.46–3.54 (1H, m, H-5'a), 3.20–3.36 (1H, m, H-5'b), 2.50–2.60 (1H, m, H-3'a), 2.20–2.33 (1H, m, H-3'b);  $^{13}\text{C}$  NMR (75 MHz, DMSO- $d_6$ )  $\delta$  151.9, 151.6, 149.6, 145.8, 143.7, 131.2, 128.4, 128.1, 127.3, 86.4, 84.6, 78.2, 65.1, 61.6, 31.4; IR (KBr): 2114  $\text{cm}^{-1}$ ; Anal. Calcd for  $\text{C}_{29}\text{H}_{25}\text{N}_7\text{O}_2\text{Cl}$ : C, 64.74; H, 4.50; N, 18.22. Found: C, 64.75; H, 4.50; N, 18.19.
8. Compound **1a**:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.38 (1H, s, H-8), 7.93 (1H, s, H-2), 6.26 (1H, d,  $J$  = 6.2 Hz, H-1'), 6.08 (1H, bs, 6-NH), 4.90 (1H, bs, 5'-OH), 4.55 (1H, ddd,  $J$  = 11.2, 5.0, 3.8 Hz, H-2'), 4.30–4.39 (1H, m, H-4'), 4.10 (1H, bd,  $J$  = 12.2 Hz, H-5'a), 3.81 (1H, bd,  $J$  = 12.2 Hz, H-5'b), 3.20 (3H, bs, N- $\text{CH}_3$ ), 2.63 (1H, ddd,  $J$  = 15.4, 6.5, 6.5 Hz, H-3'a), 2.44 (1H, ddd,  $J$  = 13.1, 6.7, 6.7 Hz, H-3'b);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  155.5, 153.1, 138.7, 120.0, 85.8, 79.5, 62.9, 62.6, 30.9, 27.6; IR (KBr): 2115  $\text{cm}^{-1}$ ; HRMS (FAB+) calcd for  $\text{C}_{11}\text{H}_{15}\text{N}_8\text{O}_2$  ( $M + \text{H}$ ) $^+$  291.1318, found 291.1328.  
Compound **1b**:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.30 (1H, s, H-8), 7.92 (1H, s, H-2), 6.26 (1H, d,  $J$  = 6.1 Hz, H-1'), 4.53 (1H, ddd,  $J$  = 11.1, 4.8, 3.7 Hz, H-2'), 4.44 (1H, bs, 5'-OH), 4.29–4.36 (1H, m, H-4'), 4.09 (1H, dd,  $J$  = 12.4, 2.3 Hz, H-5'a), 3.81 (1H, bd,  $J$  = 12.4 Hz, H-5'b), 3.54 (6H, bs, N( $\text{CH}_3$ ) $_2$ ), 2.61 (1H, ddd,  $J$  = 15.5, 6.5, 6.5 Hz, H-3'a), 2.43 (1H, ddd,  $J$  = 12.7, 6.6, 6.6 Hz, H-3'b);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  155.0, 152.2, 150.0, 137.2, 120.4, 85.9, 79.3, 62.9, 62.7, 38.6, 30.7; IR (KBr): 2115  $\text{cm}^{-1}$ ; HRMS (FAB+) calcd for  $\text{C}_{12}\text{H}_{17}\text{N}_8\text{O}_2$  ( $M + \text{H}$ ) $^+$  305.1474, found 305.1479.  
Compound **1c**:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.45 (1H, s, H-8), 7.93 (1H, s, H-2), 6.25 (1H, d,  $J$  = 6.2 Hz, H-1'), 6.05 (1H, bs, 6-NH), 4.55 (2H, ddd,  $J$  = 11.0, 4.9, 3.7 Hz, H-2'+5'-OH), 4.31–4.38 (1H, m, H-4'), 4.11 (1H, bd,  $J$  = 12.5 Hz, H-5'a), 3.78–3.85 (1H, m, H-5'b), 3.02 (1H, bm, cyclopropane), 2.65 (1H, ddd,  $J$  = 15.5, 6.5, 6.5 Hz, H-3'a), 2.45 (1H, ddd,  $J$  = 13.2, 6.6, 6.6 Hz, H-3'b), 0.91–0.98 (2H, m, cyclopropane), 0.65–0.70 (2H, m, cyclopropane);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  155.4, 152.9, 148.2, 138.8, 119.0, 84.4, 79.1, 62.3, 61.9, 30.3, 23.4, 7.0, 6.8; IR (KBr): 2113  $\text{cm}^{-1}$ ; HRMS (FAB+) calcd for  $\text{C}_{13}\text{H}_{17}\text{N}_8\text{O}_2$  ( $M + \text{H}$ ) $^+$  317.1474, found 317.1472.  
Compound **1d**:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.35 (1H, s, H-8), 7.93 (1H, s, H-2), 6.25 (1H, d,  $J$  = 6.1 Hz, H-1'), 5.98 (1H, bs, 6-NH), 4.61 (1H, bs, 5'-OH), 4.55 (1H, ddd,  $J$  = 10.7, 4.9, 3.7 Hz, H-2'), 4.30–4.38 (1H, m, H-4'), 4.09 (1H, dd,  $J$  = 12.6, 2.2 Hz, H-5'a), 3.81 (1H, dd,  $J$  = 12.6, 3.3 Hz, H-5'b), 2.62 (1H, ddd,  $J$  = 15.3, 6.5, 6.5 Hz, H-3'a), 2.44 (1H, ddd,  $J$  = 13.1, 6.7, 6.7 Hz, H-3'b), 2.06–2.21 (2H, m, cyclopentane), 1.50–1.84 (7H, m, cyclopentane);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  154.6, 153.1, 138.6, 120.1, 86.1, 79.5, 62.9, 62.6, 52.4, 33.4, 30.6, 32.7; IR (KBr): 2112  $\text{cm}^{-1}$ ; HRMS (FAB+) calcd for  $\text{C}_{15}\text{H}_{21}\text{N}_8\text{O}_2$  ( $M + \text{H}$ ) $^+$  345.1787, found 345.1777.



# ANTIVIRAL ACTIVITY OF ADENINE NUCLEOSIDES

1057

Compound **1e**:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.33 (1H, s, H-8), 7.93 (1H, s H-2), 6.24 (1H, d,  $J = 6.0$  Hz, H-1'), 5.80 (1H, bs, 6-NH), 4.72 (1H, bs, 5'-OH), 4.54 (1H, ddd,  $J = 10.8, 4.8, 3.7$  Hz, H-2'), 4.29–4.38 (1H, m, H-4'), 4.09 (1H, dd,  $J = 12.6, 2.2$  Hz, H-5'a), 3.81 (1H, dd,  $J = 12.6, 3.2$  Hz, H-5'b), 2.62 (1H, ddd,  $J = 15.2, 6.4, 6.4$  Hz, H-3'a), 2.44 (1H, ddd,  $J = 13.2, 6.7, 6.7$  Hz, H-3'b), 2.04–2.16 (2H, m, cyclohexane), 1.20–1.86 (9H, m, cyclohexane);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  153.9, 153.1, 148.2, 138.4, 119.0, 85.0, 79.1, 62.5, 62.3, 49.1, 33.0, 30.5, 25.4, 24.7; IR (KBr):  $2111\text{ cm}^{-1}$ ; HRMS (FAB+) calcd for  $\text{C}_{16}\text{H}_{23}\text{N}_8\text{O}_2$  ( $\text{M} + \text{H}$ ) $^+$  359.1944, found 359.1953.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002490>